MedTrace Logo

Persica 002 Phase 1b PP353 vs Placebo in the Treatment of Low Back Pain

NCT04238676 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 43

Last updated 2026-03-27

Study results available
· View outcomes & findings →

Summary

A Phase 1b study to investigate the efficacy of PP353 compared to placebo in the treatment of chronic low back pain associated with bone oedema.

Conditions

  • Chronic Low-back Pain

Interventions

DRUG

PP353

active administered by intradiscal injection

OTHER

Placebo

Sham injection

Sponsors & Collaborators

  • Micron Research Ltd

    collaborator UNKNOWN

  • Persica Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Duncan McHale, MBBS MRCP · Weatherden Ltd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-20
Primary Completion
2024-12-09
Completion
2024-12-09

Countries

  • Denmark
  • New Zealand
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04238676 on ClinicalTrials.gov